Pharmaceutical

AZD-9550 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

AZD-9550 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Dec 26, 2023 - 18:00
AZD-9550 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Read the original article

Tags:

Previous Article

ADRX-0706 by Adcentrx Therapeutics for Head And Neck Squamous Cell Carcinoma (HN...

Next Article

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Gilead gains EC approval for metastatic breast cancer drug Trodelvy

Gilead gains EC approval for metastatic breast cancer d...

Jul 29, 2023

Anima Biotech’s machine learning programme ‘reveals new mRNA drug targets’

Anima Biotech’s machine learning programme ‘reveals new...

Oct 10, 2024

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

Opinion: Compounding pharmacies offer a fix for shortag...

May 15, 2023